Yangtze River Pharmaceutical Group Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 28, 2027The maintenance fee for PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof (US 10,544,137) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 22, 2026
- Nov 17 US 12,799,121 Substituted Pyrazolo[1,5-a]pyrimidine-7-amine Derivatives, Compositions and Pharmaceutical Uses Thereof
- Nov 10 US 12,790,342 Pharmaceutically Acceptable Salt of Mor Receptor Agonist, and Polymorph Thereof and Use Thereof
- Oct 27 US 12,774,282 Oxaspiro Substituted Pyrrolopyrazole Derivative, Intermediate Thereof, and Preparation Method Therefor
- Sep 29 US 12,746,241 Solid Pharmaceutical Preparation, Preparation Method Therefor and Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,820,692 | Tetrahydro Isoquinoline Derivatives, Preparation Methods and Medicinal Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,100,047 | Piperidine derivatives as orexin receptor antagonist In force · USPTO record | In force | USPTO record | |
| US 9,884,870 | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof In force · USPTO record | In force | USPTO record | |
| US 10,227,324 | 2-Morpholin-4,6-Disubstituted Pyrimidine Derivative, and Preparation Method and Pharmaceutical Use Thereof In force · High confidence | In force | High confidence | |
| US 10,668,066 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof In force · USPTO record | In force | USPTO record | |
| US 10,874,674 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof In force · USPTO record | In force | USPTO record | |
| US 10,898,486 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof In force · USPTO record | In force | USPTO record | |
| US 10,912,775 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof In force · USPTO record | In force | USPTO record | |
| US 10,815,197 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors In force · USPTO record | In force | USPTO record | |
| US 10,544,137 | PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 18: 13 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 10 no status recorded